Research into the remarkable workings of the human eye have led to the acknowledgement of the presence of inherent higher order aberrations (HOAs) of the cornea, such as coma and spherical aberration. These aberrations are known to lead to optical degradation with the most significant culprit being spherical aberration.
Boston Micromachines Corporation has developed an enhanced deformable mirror capable of meeting the criteria for ultra-high resolution retinal imaging.
Bausch & Lomb has announced the launch of three new products onto the European market.
Special report focusing on all things retinal
A veterinary ophthalmologist from the USA is working on a microchip implant to help blind cats see.
The UK Royal National Institute of the Blind (RNIB) is launching a campaign encouraging glaucoma patients to follow their medical advice more thoroughly, in order to prevent needless loss of sight.
Patients with retinitis pigmentosa (RP) could benefit from continued treatment with a topical form of carbonic anhydrase inhibitor.
Advanced Medical Optics (AMO) has acquired two companies in a spending spree that has cost it approximately $828 million.
Sirion Therapeutics has made an exclusive licensing agreement with the French company, Laboratoires Thea, for the rights to develop and market a topical, anti–viral, ophthalmic gel (Virgan) in the US.
NovaVision's Vision Restoration Therapy (VRT) offers an effective rehabilitation intervention for patients with visual field defects resulting from stroke and traumatic brain injury, according to data presented at the 2007 International Stroke Conference, San Francisco, USA.
Is it possible to "zap" vitreous floaters away? John Karickhoff, Virginia, USA, thinks so and has performed 1,400 procedures over the last 15 years, despite most ophthalmologists thinking that it is unnecessary.
By using calibrated axial length readings obtained with partial optical coherence interferometry (PCI) and intraocular lens (IOL) power calculation formulas incorporating anterior chamber depth (ACD) prediction algorithms, the accuracy of power calculations can be greatly improved, according to study published in the February issue of Acta Ophthalmologica Scandinavia.
Thickness measurements of the central macular region can be used to differentiate between eyes with and without diffuse clinically significant macular oedema (CSMO), but not between eye with or without foveal CSMO, according to a study published in the February issue of Acta Ophthalmologica Scandinavia.
Sirion Therapeutics has begun enrolment for a Phase II trial of the compound fenretinide, as a treatment for geographic atrophy in patients with age-related macular degeneration.
Optos, the retinal imaging device company, has appointed Thomas W. Butts as its new Chief Executive Officer.
Ranibizumab (Lucentis) helps improve anatomic outcomes in patients with neovascular age-related macular degeneration (AMD), according to Nancy HoleKamp, MD speaking at the retina free paper session at the 2006 AAO meeting in Las Vegas.
QLT has entered into a two-year research collaboration with the Wilmer Eye Institute at John Hopkins University, USA, to research and develop potential treatments for dry age-related macular degeneration (AMD).
Combined analysis of two clinical glaucoma trials, presented at the American Academy of Ophthalmology annual meeting, suggests that it would be beneficial for ophthalmologists to use a five-year risk assessment model to better predict which patients have an increased risk of developing glaucoma.
It is now possible, for the first time, to biopsy tissue from a living eye in order to determine which tumours possess high metastatic risk, according to a report in the November 2006 issue of Ophthalmology.
Intraocular lens (IOL) power, following primary lens implantation in infants, can be calculated reasonably accurately using current formulae, according to a report published online (December 2006) ahead of print in the British Journal of Ophthalmology.
Aqueous Pharma has received European Union approval for its three layered artificial tear formula for dry eye, FreshKote.
Triamcinolone acetonide injections for macular oedema associated with retinal vein occlusion have become a therapeutic mainstay, but conflicting data has emerged about the safety of these injections, and some reports indicate that visual stabilization rather than visual improvement is occurring, according to research presented at the 2006 meeting of the AAO in Las Vegas.
Foveal outer segment/pigment epithelial thickness (FOSPET) is significantly thinner in patients with retinitis pigmentosa (RP) than in normal eyes and also shows correlation in logMAR visual acuity (VA), indicating it may be a predictor of VA in RP, according to a study published in the December 2006 issue of the American Journal of Ophthalmology.
Greater central corneal thickness (CCT) measurements are observed in those with ocular hypertension than in those without, according to a report published online ahead of publication in Ophthalmology.
UVA induced collagen crosslinking (CCL) followed by surface excimer ablation shows promise as a safe and effective technique for visual rehabilitation in eyes with keratoconus or postLASIK ectasia, said A. John Kanellopoulos, MD, speaking at the 2006 AAO meeting in Las Vegas.
Patients with open-angle glaucoma and ocular hypertension with thinner corneas show significantly greater shallowing of the cup and smaller improvements of neuroretinal rim blood flow after intraocular pressure (IOP) reduction, according to a report in the November 2006 issue of Archives of Ophthalmology.
The Anecortave Acetate Risk Reduction Trial (AARRT) has met its patient enrollment requirement of almost 2,600 individuals who are at high risk for developing choroidal neovascularization (CNV) or advanced age-related macular degeneration (AMD) over time, reported Jason Slakter, MD, of the Vitreous-Retina-Macular Consultants of New York, USA at the 2006 meeting of the AAO in Las Vegas.
The US LASIK Vision Institute has re-launched its web site to provide consumers with more information about laser vision correction services and the qualifications of its independent doctors.
ISTA Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its eye drop formulation of bepotastine for the treatment of allergic conjunctivitis.
iCo Therapeutics, an Isis Pharmaceuticals licensee, has filed an Investigational New Drug (IND) application with the FDA for iCo-007.